As a CRO specialising in psychedelics, we're currently engaged in nine trials encompassing a variety of drugs and therapy modalities, ranging from intensive therapy sessions to minimal psychological support. Broadly, these trials fall into two approaches: one aims to maximise efficacy by integrating therapy with the drug, while the other seeks to isolate the drug's effects by minimising therapy. Through these trials, we can discern what approaches yield favourable results and which do not.